Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Chimeric Antigen Receptor T Cell-Related Neurotoxicity: Mechanisms, Clinical Presentation, and Approach to Treatment
Jessica Rice, Sarah Nagle, Julie Randall, et al.
Current Treatment Options in Neurology (2019) Vol. 21, Iss. 8
Closed Access | Times Cited: 83

Showing 1-25 of 83 citing articles:

Peripheral inflammation and blood–brain barrier disruption: effects and mechanisms
Xiaowen Huang, Basharat Hussain, Junlei Chang
CNS Neuroscience & Therapeutics (2020) Vol. 27, Iss. 1, pp. 36-47
Open Access | Times Cited: 392
The blood–brain barrier in systemic infection and inflammation
Ian Galea
Cellular and Molecular Immunology (2021) Vol. 18, Iss. 11, pp. 2489-2501
Open Access | Times Cited: 371
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology
John A. Thompson, Bryan J. Schneider, Julie R. Brahmer, et al.
Journal of the National Comprehensive Cancer Network (2022) Vol. 20, Iss. 4, pp. 387-405
Open Access | Times Cited: 303
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
Marcela V. Maus, S. Alexander, Michael R. Bishop, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 2, pp. e001511-e001511
Open Access | Times Cited: 210
Cytokines in CAR T Cell–Associated Neurotoxicity
Juliane Gust, Rafael Ponce, W. Conrad Liles, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 159
Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma
Darel Martínez Bedoya, Valérie Dutoit, Denis Migliorini
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 111
Brain dysfunction in COVID‐19 and CAR‐T therapy: cytokine storm‐associated encephalopathy
Umberto Pensato, Lorenzo Muccioli, Ilaria Cani, et al.
Annals of Clinical and Translational Neurology (2021) Vol. 8, Iss. 4, pp. 968-979
Open Access | Times Cited: 71
Advances in NK cell production
Fang Fang, Siqi Xie, Minhua Chen, et al.
Cellular and Molecular Immunology (2022) Vol. 19, Iss. 4, pp. 460-481
Open Access | Times Cited: 67
Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy
Robert C. Sterner, Rosalie M. Sterner
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 50
Blood brain barrier and inflammation in depression
Eva M. Medina‐Rodríguez, Eléonore Beurel
Neurobiology of Disease (2022) Vol. 175, pp. 105926-105926
Open Access | Times Cited: 41
Use of CAR-T cell therapy, PD-1 blockade, and their combination for the treatment of hematological malignancies
Wenting Song, Mingzhi Zhang
Clinical Immunology (2020) Vol. 214, pp. 108382-108382
Closed Access | Times Cited: 51
Chimeric Antigen Receptor T-Cells in B-Acute Lymphoblastic Leukemia: State of the Art and Future Directions
Uri Greenbaum, Kris M. Mahadeo, Partow Kebriaei, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 51
Challenges and Clinical Strategies of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Overview and Developments
Xinjie Xu, Shengkang Huang, Xinyi Xiao, et al.
Frontiers in Immunology (2021) Vol. 11
Open Access | Times Cited: 48
A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions
Faroogh Marofi, Heshu Sulaiman Rahman, Muhammad Harun Achmad, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 48
Patient-Reported Symptom and Functioning Status during the First 12 Months after Chimeric Antigen Receptor T Cell Therapy for Hematologic Malignancies
Xin Shelley Wang, Samer A. Srour, Meagan Whisenant, et al.
Transplantation and Cellular Therapy (2021) Vol. 27, Iss. 11, pp. 930.e1-930.e10
Open Access | Times Cited: 47
Promoter usage regulating the surface density of CAR molecules may modulate the kinetics of CAR-T cells in vivo
Jin‐Yuan Ho, Lin Wang, Ying Liu, et al.
Molecular Therapy — Methods & Clinical Development (2021) Vol. 21, pp. 237-246
Open Access | Times Cited: 39
Therapeutic Potential of TNFα and IL1β Blockade for CRS/ICANS in CAR-T Therapy via Ameliorating Endothelial Activation
Yunshuo Chen, Ranran Li, Siqi Shang, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 37
Primary vs. pre-emptive anti-seizure medication prophylaxis in anti-CD19 CAR T-cell therapy
Umberto Pensato, Federica Pondrelli, Chiara De Philippis, et al.
Neurological Sciences (2024) Vol. 45, Iss. 8, pp. 4007-4014
Open Access | Times Cited: 5
Recent Updates on Chimeric Antigen Receptor T-Cell Approaches in Cancer Immunotherapy
Maryam Sahlolbei, Amirhossein Ahmadieh-Yazdi, Mohadeseh Rostamipoor, et al.
IntechOpen eBooks (2024)
Open Access | Times Cited: 5
Neurotoxic complications of chimeric antigen receptor (CAR) T-cell therapy
Frederick W. Vonberg, Imran Riaz Malik, Maeve O’Reilly, et al.
Journal of Neurology Neurosurgery & Psychiatry (2025), pp. jnnp-333924
Closed Access
A New Era in Endothelial Injury Syndromes: Toxicity of CAR-T Cells and the Role of Immunity
Eleni Gavriilaki, Ioanna Sakellari, Maria Gavriilaki, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 11, pp. 3886-3886
Open Access | Times Cited: 38
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
Nina Shah, Jack Aiello, David Avigan, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 2, pp. e000734-e000734
Open Access | Times Cited: 37
Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma
Zixun Yin, Ya Zhang, Xin Wang
Biomarker Research (2021) Vol. 9, Iss. 1
Open Access | Times Cited: 31
Neurological Complications of Conventional and Novel Anticancer Treatments
Paola Alberti, Alessandro Salvalaggio, Andreas A. Argyriou, et al.
Cancers (2022) Vol. 14, Iss. 24, pp. 6088-6088
Open Access | Times Cited: 21
Chimeric antigen receptor T-cell therapy-induced nervous system toxicity: a real-world study based on the FDA Adverse Event Reporting System database
Xiayang Ren, Guanmin Zhang, Guohui Li, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top